Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Natural SARS-CoV-2 antibodies persist for six months in children

Researchers investigate the presence of antibodies against SARS-CoV-2 in children between the ages of five and 19 after infection.

28 Mar 2022

Evaluating severity of influenza infection in ferrets with COVID-19 history

In a new study, researchers investigated the effect of SARS-CoV-2 exposure on the severity of influenza in ferrets.

28 Mar 2022

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

A recent study investigated the potency and functionality of T-cell and humoral responses against the SARS-CoV-2 wild-type strain and its variants.

28 Mar 2022

Benefits of heterotypic vaccination against variants of SARS-CoV-2

A new study evaluated the antibody responses against the newly emerged SARS-CoV-2 Omicron variant upon heterotypic vaccination in animal models.

28 Mar 2022

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Researchers designed a dynamic mathematical model to simulate the transmission of the SARS-CoV-2 Omicron variant in China and project its associated burden on healthcare facilities, should the zero-COVID-19 policy be lifted.

28 Mar 2022

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Researchers evaluated the ability of RBD antibodies to bind to and neutralize SARS-CoV-2 Omicron variant.

28 Mar 2022

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

A new research paper published as an early release manuscript in the Nature Medicine journal compares the sensitivity of this strain as well as the earlier Delta and the newer BA.2 to therapeutic mAbs.

27 Mar 2022

SARS-CoV-2 antibodies in breast milk remain after Holder pasteurization

Researchers study the impact of pasteurization on specific Ig concentration against SARS-CoV-2 in milk from mRNA vaccinated lactating women.

27 Mar 2022

Study evaluates efficacy of sarilumab in severe/critical COVID-19 patients

Researchers discuss the results of a clinical trial to assess the efficacy and safety of IV sarilumab for the treatment of hospitalized COVID-19 patients.

27 Mar 2022

Novel SARS-CoV-2 strains found to have low impact on CD8 T lymphocytes

Researchers investigated the impact of mutations in the SARS-CoV-2 variants of interest and variants of concern on the properties of the cluster of differentiation 8 T lymphocytes.

25 Mar 2022

New insights into SARS-CoV-2 immunity gained from natural infection

Antibody-secreting cells (ASCs) peaked at 3-4 weeks and were still being produced at 3-4 months in patients hospitalized with COVID-19, according to a study published in the peer-reviewed journal Viral Immunology.

25 Mar 2022

How the timing and dose of different types of passive antibody treatments predict protection from SARS-CoV-2 infection

A new study has focussed on conducting a systematic search of the literature and aggregated data associated with randomized control trials of passive antibody therapy.

25 Mar 2022

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

A recent study presented topologically engineered fragment crystallizable-fusion proteins and antibodies as therapeutic options for diseases like human coronaviruses infections and cancers.

25 Mar 2022

Evusheld™ found to poorly neutralize Omicron in kidney transplant patients

Researchers evaluated the neutralizing antibody titers and anti-receptor-binding domain immunoglobulin G titers in sera of kidney transplant recipients who were vaccinated against COVID-19 and treated with 300 mg dosage of Evusheld™

25 Mar 2022

Researchers characterize vaccines for infectious bronchitis virus

A new study characterized the genetic and immunological aspects of the infectious bronchitis virus (IBV) vaccines commercially used in Korea.

25 Mar 2022

Adaptive immunity against SARS-CoV-2 is persistent and robust in COVID-convalescent children

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection incites adaptive cellular immune responses. In many SARS-CoV-2 studies, peripheral blood is analyzed to study the immune responses. Now, a new study under consideration at the Nature Portfolio Journal analyzes the peripheral blood, tonsils, and adenoids of children to understand local and systemic immune responses to SARS-CoV-2.

25 Mar 2022

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

A team of international scientists has developed an mRNA-based coronavirus disease 2019 (COVID-19) vaccine encoding the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant. The vaccine candidate has shown high efficacy in inducing neutralizing antibodies and protecting against delta infection in mice. The study is currently available on the bioRxiv* preprint server.

24 Mar 2022

Antibody News and Research

Further Reading

Natural SARS-CoV-2 antibodies persist for six months in children

Evaluating severity of influenza infection in ferrets with COVID-19 history

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

Benefits of heterotypic vaccination against variants of SARS-CoV-2

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

SARS-CoV-2 antibodies in breast milk remain after Holder pasteurization

Study evaluates efficacy of sarilumab in severe/critical COVID-19 patients

Novel SARS-CoV-2 strains found to have low impact on CD8 T lymphocytes

New insights into SARS-CoV-2 immunity gained from natural infection

How the timing and dose of different types of passive antibody treatments predict protection from SARS-CoV-2 infection

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

Evusheld™ found to poorly neutralize Omicron in kidney transplant patients

Researchers characterize vaccines for infectious bronchitis virus

Adaptive immunity against SARS-CoV-2 is persistent and robust in COVID-convalescent children

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

Study investigates anti-SARS-CoV-2 antibody levels following Pfizer vaccine primary and booster regimens

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

Study evaluates humoral and cellular immune memory induced by different COVID-19 vaccines

Event guide: Targeted Therapies Partnering & Licensing Summit Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo